Sabby Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Sabby Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-11,500	Closed	-$1.37M	–	144
2018 Q1	$1.37M	Sell	11,500 -7,750	-40%	-$999K	0.16%	51
2017 Q4	$2.45M	Buy	+19,250	New	+$2.42M	0.22%	49
2017 Q1	–	Sell	-13,823	Closed	-$639K	–	262
2016 Q4	$518K	Buy	+13,823	New	+$579K	0.03%	194
2015 Q4	–	Sell	-6,809	Closed	-$547K	–	322
2015 Q3	$547K	Buy	+6,809	New	+$757K	0.02%	286
2014 Q3	–	Sell	-12,000	Closed	-$774K	–	261
2014 Q2	$758K	Buy	+12,000	New	+$713K	0.03%	172

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Sabby Management's ALNY Position: Q2 2018 in Review

Sabby Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2018, closing a stake of 11,500 shares — an estimated $1.37M sold.

Sabby Management first reported a position in ALNY in Q2 2014 and held it in 5 quarters. The position peaked at $2.45M in Q4 2017. 310 funds tracked by Wall St. Rank hold ALNY as of Q2 2018.

Sabby Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Sabby Management sold 11,500 Alnylam Pharmaceuticals shares in Q2 2018, an estimated $1.37M.
Sabby Management first reported a position in Alnylam Pharmaceuticals in Q2 2014 and held it in 5 quarters.
Sabby Management's Alnylam Pharmaceuticals position peaked at $2.45M in Q4 2017.
310 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2018.

Based on Sabby Management's 13F filing for Q2 2018, filed 14 Aug 2018.